Casdatifan
- Generic Name
- Casdatifan
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06919991
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Phase 1
Recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 140
- Registration Number
- NCT06191796
- Locations
- 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸Exelixis Site #9, Miami, Florida, United States
🇺🇸Exelixis Clinical Site #1, Orlando, Florida, United States
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05999513
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorsClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05536141
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at San Diego, San Diego, California, United States
🇺🇸Medical Oncology Associates Summit Cancer Centers, Spokane, Washington, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05117554
- Locations
- 🇳🇱
Investigational Site, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath